培菲康治疗前后肠易激综合征患者相关肠道益生菌群变化分析_临床医学论文.docVIP

培菲康治疗前后肠易激综合征患者相关肠道益生菌群变化分析_临床医学论文 培菲康治疗前后肠易激综合征患者相关肠道益生菌群变化分析_临床医学论文 【摘要】 目的 观察培菲康治疗前后肠易激综合征(IBS)患者肠道相关益生菌群的变化。方法 选取符合罗马Ⅲ标准的IBS患者60例及年龄、性别相匹配的对照人群20人，IBS患者包括腹泻型、便秘型、混合型、未分型4种类型，再将IBS患者随机分为2亚组，治疗组予以培菲康治疗，2片，3次/d，疗程为4周，对照组予以安慰剂治疗4周，比较治疗前后患者粪便中双歧杆菌和乳杆菌数量的变化。结果 腹泻型IBS患者粪便中双歧杆菌及乳杆菌含量均小于正常人群(0.01)，混合型IBS患者粪便中双歧杆菌含量小于正常人群(0.01);服用培菲康4周后，患者粪便中双歧杆菌及乳杆菌含量均高于治疗前(0.01);以腹泻为主的IBS患者中，治疗有效者，治疗后粪便中双歧杆菌和乳杆菌含量都要少于治疗无效者(0.01)。结论 IBS患者存在某种肠道菌群的量的变化，且外源性补充相关益生菌制剂时，患者病情的变化伴有粪便中益生菌群的变化。 【关键词】 肠易激综合征;益生菌;荧光定量PCR;肠道菌群 　　Abstract: Objective To analysis of the fecal Bifidobacterium spp. and Lactobacillus spp. in patients with irritable bowel syndrome (IBS) before and after treatment with bifid triple viable capsules for 4 weeks. Methods 60 participants with IBS, as defined by the Rome III criteria, were compared with age- and gender-matched control subjects (n=20). The IBS patients were divided into diarrhea group, constipation group, alternating group and unclassified group. The patients in the diarrhea and constipation groups were further divided into treatment group (2 capsules, 3 times daily for 4 weeks) and the control group (placebo administration for 4 weeks). The variations in the number of the fecal Bifidobacterium spp. and Lactobacillus spp. were analyzed before and after the intervention, using quantitative Real-time PCR.Results In the IBS patients with diarrhea, the amount of Bifidobacterium spp. and Lactobacillus spp. were smaller than that in healthy population (0.01), and in the IBS patients of alternating type, the amount of Bifidobacterium spp. was smaller than that in healthy population (0.01). 4 weeks after the treatment, the amounts of Bifidobacterium spp. and Lactobacillus spp. in all patients increased (0.01). Diarrhea-predominant IBS patients who had improvements in the Symptom Severity Score of IBS carried smaller amounts of Bifidobacterium spp. and Lactobacillus spp. than patients who had no improvement.Conclusion There are variations in the amounts of certain gut m